

T - Index

In this guide

[In this guide](#)

1. [A - Index](#)
2. [B - Index](#)
3. [C - Index](#)
4. [D - Index](#)
5. [E - Index](#)
6. [F - Index](#)
7. [G - Index](#)
8. [H - Index](#)
9. [I - Index](#)
10. [J - Index](#)
11. [K - Index](#)
12. [L - Index](#)
13. [M - Index](#)
14. [N - Index](#)
15. [O - Index](#)
16. [P - Index](#)
17. [Q - Index](#)
18. [R - Index](#)
19. [S - Index](#)
20. [T - Index](#)
21. [U - Index](#)
22. [V - Index](#)
23. [W - Index](#)
24. [X - Index](#)
25. [Y - Index](#)
26. [Z - Index](#)

Subject:**Year Page****Terephthalic acid**

<i>In vitro</i> and <i>in vivo</i> mutagenicity	2001 87
endocrine disrupting effects, urinary bladder and the kidney	2003 13
<i>In vivo</i> mutagenicity	2007 135
TDI and updated COT statement on	2008 16
and isophthalic acids in food	2000 24
multigenerational reproduction study additional histopathological examinations	2005 10
Update statement on the Toxicology of	2008 21

Subject:**Year Page****Toxins**

T2-toxin and HT2-toxin and neosolaniol in the diet of infants aged 0-1 and young children aged 1-5 years.	2018 15
-----------------------------------------------------------------------------------------------------------	---------

Subject:**Year Page****Test strategies and evaluations**

Continued advice, OECD recommendations, standardisation of genotoxicity test procedures	1993 39
-----------------------------------------------------------------------------------------	---------

finalise the updating of 7 existing guidelines and to consider 2 new guidelines.	1994 25
interpretation of genotoxicity tests chemical mutagenesis	1995 37
advice on strategies in carcinogenicity for the ongoing discussions of the International Conference on	1996 44
Harmonisation of the Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).	1996 75
test strategies and interpretation of genotoxicity tests in the context of the discussions of the Genotoxicity Working Party of the International Conference on Harmonisation of the Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).	1997 75, 112
review of its guidelines for the testing of chemicals for mutagenicity	1998 34, 50
revision of guidelines on an appropriate strategy for the testing of chemicals for mutagenicity & evaluation of chemically induced aneuploidy and in particular the extrapolation of data from somatic cells to germ cells.	2000 63
In vitro micronucleus test	2002 88
ILSI/HESI research programme on alternative cancer models: results of Syrian hamster embryo cell transformation assay	2002 87
IGHRC paper on uncertainty factors	2002 129
Minimum duration of carcinogenicity studies in rats	2002 130

Short term tests for carcinogenicity. (ILSI/HESI research programme on alternative cancer models)	2002 131
The investigation of interaction between genotype and chemicals in the environment on the induction of cancer	2002 132
In-vitro Mammalian cell mutation assays	2003 137
Strategy for investigating germ cell mutagens	2003 138
Significance of in-vivo mutagenicity at high doses	2003 139
COC guidance on a strategy for risk assessment of carcinogens	2004 188 to 190
COT/COC/COM review of toxicogenomics	2004 190, 191
approaches to test strategies for chemicals which were positive in in vitro mutagenicity tests	2006 240
TK6 GADD45a GFP genotoxicity assay as an early screening assay to be undertaken prior to in-vitro mutagenicity testing.	2007 137
development of an OECD guideline for the in vitro micronucleus test	2007 137
Review of COM Guidance 2000	2008 234
Risk assessment of in-vivo mutagens (and genotoxic carcinogens)	2001 89
Tobacco induced lung carcinogenesis: The importance of p53 mutations	2001 89

Subject:**Testicular cancer****Year Page**

Review of the possible chemical aetiology of, 2006 284

Subject:**2,3,7,8-Tetrachlorodibenzo-p-dioxin
(TCDD)****Year Page**

as a possible human carcinogen

1993 49

Developmental and reproductive toxicity, Immunotoxicity,
Carcinogenicity, Exposure from human milk1995 15,
64

Review, Consideration of IARC Monograph Published in 1997

1998 45

review of the relevant literature published since 1990

1999 49

Carcinogenicity of

2001 115

Subject:**Tetrabromobisphenol A (TBBPA)****Year Page**

Tetrabromobisphenol A

2004 12

review of toxicological data

2004 62

Subject:**Year Page****Tetrachloroethylene**

Perchloroethylene, risk of developmental toxicity 1993 21,
48

review the animal and human carcinogenicity data on this compound with particular reference to the recent epidemiology 1996 37,
68

reproductive and developmental toxicity arising from exposure to 1997 47

Subject:**Year Page****Thalidomide**

Mutagenicity of, 1997 62

Subject:**Year Page****Thiabendazole**

development of the fetus 1991 20

developmental toxicity 1995 20

as a potential in-vivo aneugen 1996 40

COT evaluation of ; ADI 1997 50

Subject:

Thiamphenicol **Year Page**

potential to cause idiopathic blood dyscrasia 1992 26

Subject:

Thresholds for aneuploidy inducing chemicals **Year Page**

in-vivo assays 1995 37

Studies on Benomyl and Carbendazim 1996 42

Thresholds for *in vivo* mutagens 2009 151

Threshold for benzene induced carcinogenicity, Consideration of evidence for 1998 32

Subject:

Titanium dioxide **Year Page**

Review of 2021 EFSA opinion 2021 23, 60

Interim position paper, ongoing work 2021 37

Subject:**Year Page****Tobacco**

toxicological evaluation of tobacco, ingredients and additives used in the manufacture of tobacco, and its emission products.	2008	14
genotoxicity of	2009	53
Reassessment of the toxicological testing of tobacco	2004	19, 107,
Reassessment of toxicology of tobacco products	2004	142, 186
Carcinogenicity testing of	2009	219
reassessment of the toxicological testing of	2004	19, 107
reassessment of the toxicology of	2004	142, 186
Tobacco induced lung carcinogenesis: the importance of p53 mutations	2001	107

Subject:**Year Page****Toltrazuril**

Advice on,	1992	57
------------	------	----

Subject:**Toxicity of chemicals in the infant diet;
and the diet of young children aged 1 to
5 years****Year Page**

Aluminium, lead, vitamin A, soy phytoestrogens 2012 22

α -, β - and γ -hexachlorocyclohexanes and perfluorooctane sulphonate 2013 32

Reviews of vitamin A, iodine and nickel commenced in 2016 and will continue in 2017 2016 22

manganese, chromium and copper 2017 27

Mycotoxins were reviewed in 2017 and full reviews of T2,HT2 and neosolaniol and ochratoxin A commenced in 2017. 2017 27

Statements on nickel and cadmium had been finalised in 2017 2017 28

Subject:**Toxicogenomics****Year Page**

in toxicology, ongoing review of new relevant in vitro studies 2007 137,
185

COM ongoing review 2008 235

COT/COC/COM update their joint statement on toxicogenomics published in 2004 2009 60

as a tool for identifying genotoxic carcinogens	2013 46
use of in toxicology (update on statement published in 2002)	2004 22, 112
COT/COC/COM review of	2004 144
in toxicology – design, analysis and statistical issues	2010 29
Toxicological aspects of the SACN report on Iron	2009 29
In toxicology testing, presentation on	2021 58
Toxicological evaluation of chemical analyses carried out as part of a pilot study for a breast milk archive	2004 14, 70
Toxicogenomics data in risk assessment	2012 16
ToxTracker	2019 34, 52
Transgenerational Epigenetics, Workshop on	2008 19, 36
Use of toxicogenomics in toxicology (update on statement published in 2002).	2004 22, 112

Subject:

Transgenerational Epigenetics

Workshop and implications for risk assessment	2008 19,36
Environmental toxicant induced, presentation on	2021 56

Subject:**Year Page****Transgenic animal models**

Transgenic animal models, Use in short terms tests for carcinogenicity

2001 142

Transgenic mouse models

1997 114

Validation of short-term carcinogenicity tests using transgenic animals, Presentation on

1999 73

Subject:**Year Page****Trichloroethylene**

Trichloroethylene

1996 39, 71

Subject:**Year Page****Trihalomethanes in drinking water**

Chloroform, Bromodichloromethane [BDCM], Chlorodibromomethane [DBCM] and Bromoform

1994 22, 32, 69

Bromodichloromethane, Chlorodibromomethane, and Bromoform.

1995 35

Subject:**Year Page****Tryptophan and eosinophilia-myalgia syndrome**

risk to health of tryptophan, particularly in food supplements	2003	21
one or more contaminants in several batches of tryptophan produced by one manufacturer	2004	12, 83

Subject:

Year Page

Tryptophan in food

responses to consultation on revision of Regulations 2005 11

Subject:

Year Page

Turmeric

supplements- potential; hepatotoxicity of 2019 16

Subject:

Year Page

Type 1 caramel

Mutagenicity data, 1991 30